Patents Assigned to Alchemia Oncology Pty Limited
-
Patent number: 9066919Abstract: This application provides methods and compositions for the treatment of cancer. The application provides compositions including hyaluronic acid and a chemotherapeutic agent such as irinotecan that are useful in the treatment of cancer.Type: GrantFiled: August 5, 2005Date of Patent: June 30, 2015Assignee: Alchemia Oncology Pty LimitedInventor: Tracey J. Brown
-
Patent number: 8937052Abstract: The present invention relates generally to the field of therapeutics and in particular, chemotherapy. Even more particularly, the present invention provides therapeutic strategies which reduce the toxicity or enhance the efficacy of chemotherapeutic agents. Compositions and methods of treatment and prophylaxis are also contemplated by the present invention.Type: GrantFiled: July 27, 2006Date of Patent: January 20, 2015Assignee: Alchemia Oncology Pty LimitedInventor: Tracey J. Brown
-
Publication number: 20140328828Abstract: The present invention relates generally to treatment and prophylactic protocols for cellular disease or disorders, such as diseases and disorders associated with abnormal cellular proliferation. More particularly, the present invention provides uses of compositions comprising therapeutic antibodies and hyaluronan in the treatment or prophylaxis of cellular diseases and disorders.Type: ApplicationFiled: December 4, 2013Publication date: November 6, 2014Applicant: ALCHEMIA ONCOLOGY PTY LIMITEDInventors: Tracey J. BROWN, Gary R. BROWNLEE
-
Patent number: 8741970Abstract: The present invention relates to the enhancement of the efficacy of drugs, and more particularly, with overcoming the resistance of cells or organisms to drugs. In particular, the present invention provides a method for enhancing the effectiveness of a cytotoxic or anti-neoplastic agent, comprising the step of co-administering said agent with hyaluronan, wherein co-administration with hyaluronan enhances the agent's cancer cell-killing potential.Type: GrantFiled: December 14, 2011Date of Patent: June 3, 2014Assignee: Alchemia Oncology Pty LimitedInventor: Tracey J. Brown
-
Patent number: 8623354Abstract: The present invention relates generally to treatment and prophylactic protocols for cellular diseases or disorders, such as diseases and disorders associated with abnormal cellular proliferation. More particularly, the present invention provides compositions comprising therapeutic antibodies and hyaluronan and their use in the treatment or prophylaxis of cellular diseases and disorders.Type: GrantFiled: September 4, 2006Date of Patent: January 7, 2014Assignee: Alchemia Oncology Pty LimitedInventors: Tracey J. Brown, Gary R. Brownlee
-
Publication number: 20130197103Abstract: The present invention relates to the enhancement of the efficacy of drugs, and more particularly, with overcoming the resistance of cells or organisms to drugs. In particular, the present invention provides a method for enhancing the effectiveness of a cytotoxic or anti-neoplastic agent, comprising the step of co-administering said agent with hyaluronan, wherein co-administration with hyaluronan enhances the agent's cancer cell-killing potential.Type: ApplicationFiled: December 14, 2011Publication date: August 1, 2013Applicant: Alchemia Oncology Pty LimitedInventor: Tracey J. BROWN
-
Patent number: 8460658Abstract: The present invention relates generally to the modulation of hyaluronan (HA) synthesis and degradation. The present invention further contemplates modulation of cellular proliferation, useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis. The present invention is directed to compounds, agents, pharmaceutically active agents, medicaments, therapeutics, actives, drugs and the like which specifically target a portion of HAS which is accessible to the extracellular environment in malignant or inflammatory or proliferative cells but which portion is not accessible to the external environment in “normal” cells. A “normal” cell in this instance is a non-malignant, inflammatory or proliferative cell.Type: GrantFiled: June 13, 2011Date of Patent: June 11, 2013Assignee: Alchemia Oncology Pty LimitedInventors: Tracey J. Brown, Gary R. Brownlee
-
Patent number: 8388993Abstract: The present invention relates to the enhancement of bioavailability of chemotherapeutic agents for the treatment of disease. In particular, the present invention relates to a method of enhancing the bioavailability of a chemotherapeutic agent comprising the step of administering to a subject in need thereof a therapeutically effective amount of hyaluronan.Type: GrantFiled: May 1, 2006Date of Patent: March 5, 2013Assignee: Alchemia Oncology Pty LimitedInventor: Tracey J. Brown
-
Patent number: 8287894Abstract: This application provides methods and compositions for the treatment of cancer. The application provides compositions comprising hyaluronic acid and a chemotherapeutic agent such as irinotecan that are useful in the treatment of cancer.Type: GrantFiled: July 27, 2005Date of Patent: October 16, 2012Assignee: Alchemia Oncology Pty LimitedInventors: Tracey J. Brown, Richard M. Fox
-
Publication number: 20120009193Abstract: The present invention relates generally to the modulation of hyaluronan (HA) synthesis and degradation. More particularly, the present invention provides compositions and methods for modulating the expression of genetic material encoding HA synthase (HAS) and other enzymes or receptors primarily involved in hyaluronan metabolism; or modulating the proteins that synthesise or degrade hyaluronan including HAS function or activity. The compositions include or comprise nucleic acid molecules and interactive molecules such as antibodies and small molecule inhibitors and HAS substrate analogs. The present invention further contemplates modulation of cellular proliferation, useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis.Type: ApplicationFiled: June 13, 2011Publication date: January 12, 2012Applicant: Alchemia Oncology Pty LimitedInventors: Tracey J. Brown, Gary R. Brownlee
-
Patent number: 7985844Abstract: Modulation of Hyaluronan (HA) synthesis and degradation is disclosed by compounds and compositions that are capable of reducing the level of hyaluronan synthase (HAS) or hyaluronidase (HYAL) or the function or activity of HAS or HYAL. The compounds and compositions can also inhibit the expression of genetic material encoding these enzymes. The compounds and compositions comprise nucleic acid molecules and interactive molecules such as antibodies, small molecule inhibitors and substrate analogs of HAS and HYAL. The compounds and compositions are useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis.Type: GrantFiled: December 15, 2009Date of Patent: July 26, 2011Assignee: Alchemia Oncology Pty LimitedInventors: Tracey J. Brown, Gary R. Brownlee
-
Patent number: 7662929Abstract: Modulation of Hyaluronan (HA) synthesis and degradation is disclosed by compounds and compositions that are capable of reducing the level of hyaluronan synthase (HAS) or hyaluronidase (HYAL) or the function or activity of HAS or HYAL. The compounds and compositions can also inhibit the expression of genetic material encoding these enzymes. The compounds and compositions comprise nucleic acid molecules and interactive molecules such as antibodies, small molecule inhibitors and substrate analogs of HAS and HYAL. The compounds and compositions are useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis.Type: GrantFiled: October 11, 2004Date of Patent: February 16, 2010Assignee: Alchemia Oncology Pty LimitedInventors: Tracey J. Brown, Gary R. Brownlee
-
Publication number: 20090306012Abstract: The present invention relates to the field of chemotherapy of diseases such as cell proliferation disorders including cancer. In particular, the present invention relates to the use of hyaluronan (HA) as a protective agent in the treatment of subjects. HA is administered in conjunction with a chemotherapeutic agent to facilitate the prolonged administration of a dose of the chemotherapeutic agent to be administered to a subject. Owing to the protective effects of the HA, the dose of chemotherapeutic agent may be substantially higher than a generally accepted effective dose, which would otherwise be expected to cause unacceptable side effects in the subject.Type: ApplicationFiled: June 11, 2009Publication date: December 10, 2009Applicant: Alchemia Oncology Pty LimitedInventors: Tracey Jean BROWN, Richard Mark FOX